Note and Warrant Purchase Agreement



 Exhibit 10.1 
 NOTE AND WARRANT PURCHASE AGREEMENT 
 LAURUS MASTER FUND, LTD. 
 and 
 BIOVEST INTERNATIONAL, INC.

 Dated: March 31, 2006 







 TABLE OF CONTENTS 
  

							
	 	 	 	  	Page
	1.	 	Agreement to Sell and Purchase.	  	1
			
	2.	 	Fees and Warrant. On the Closing Date:	  	1
			
	3.	 	Closing, Delivery and Payment.	  	2
		 	3.1	  	Closing.	  	2
		 	3.2	  	Delivery	  	2
			
	4.	 	Representations and Warranties of the Company.	  	3
		 	4.1	  	Organization, Good Standing and Qualification.	  	3
		 	4.2	  	Subsidiaries.	  	4
		 	4.3	  	Capitalization; Voting Rights.	  	4
		 	4.4	  	Authorization; Binding Obligations.	  	5
		 	4.5	  	Liabilities.	  	5
		 	4.6	  	Agreements; Action.	  	5
		 	4.7	  	Obligations to Related Parties.	  	7
		 	4.8	  	Changes.	  	8
		 	4.9	  	Title to Properties and Assets; Liens, Etc.	  	9
		 	4.10	  	Intellectual Property.	  	10
		 	4.11	  	Compliance with Other Instruments.	  	10
		 	4.12	  	Litigation.	  	10
		 	4.13	  	Tax Returns and Payments.	  	11
		 	4.14	  	Employees.	  	11
		 	4.15	  	Registration Rights and Voting Rights.	  	12
		 	4.16	  	Compliance with Laws; Permits.	  	12
		 	4.17	  	Environmental and Safety Laws.	  	12
		 	4.18	  	Valid Offering.	  	13
		 	4.19	  	Full Disclosure.	  	13
		 	4.20	  	Insurance.	  	13
		 	4.21	  	SEC Reports.	  	13
		 	4.22	  	Listing.	  	14
		 	4.23	  	No Integrated Offering.	  	14
		 	4.24	  	Stop Transfer.	  	14
		 	4.25	  	Dilution.	  	14
		 	4.26	  	Patriot Act.	  	14
		 	4.27	  	ERISA.	  	15
			
	5.	 	Representations and Warranties of the Purchaser.	  	15
		 	5.1	  	Incorporation; No Shorting.	  	15
		 	5.2	  	Requisite Power and Authority.	  	15
		 	5.3	  	Investment Representations.	  	16
		 	5.4	  	The Purchaser Bears Economic Risk.	  	16
		 	5.5	  	Acquisition for Own Account.	  	16
		 	5.6	  	The Purchaser Can Protect Its Interest.	  	16
		 	5.7	  	Accredited Investor.	  	16
		 	5.8	  	Legends.	  	17
			
	6.	 	Covenants of the Company.	  	17
		 	6.1	  	Stop-Orders.	  	17

  

 i 









							
	 	 	 	  	 	  	Page(s)
		 	6.2	  	Listing.	  	17
		 	6.3	  	Market Regulations.	  	18
		 	6.4	  	Reporting Requirements.	  	18
		 	6.5	  	Use of Funds.	  	19
		 	6.6	  	Access to Facilities.	  	19
		 	6.7	  	Taxes.	  	20
		 	6.8	  	Insurance.	  	20
		 	6.9	  	Intellectual Property.	  	21
		 	6.10	  	Properties.	  	21
		 	6.11	  	Confidentiality.	  	21
		 	6.12	  	Required Approvals.	  	22
		 	6.13	  	Reissuance of Securities.	  	25
		 	6.14	  	Opinion.	  	25
		 	6.15	  	Margin Stock.	  	25
		 	6.16	  	Restricted Cash Disclosure.	  	25
		 	6.17	  	Financing Right of First Refusal.	  	25
		 	6.18	  	Authorization and Reservation of Shares.	  	26
			
	7.	 	Covenants of the Purchaser.	  	26
		 	7.1	  	Confidentiality.	  	26
		 	7.2	  	Non-Public Information.	  	26
		 	7.3	  	Limitation on Acquisition of Common Stock of the Company.	  	26
			
	8.	 	Covenants of the Company and the Purchaser Regarding Indemnification.	  	27
		 	8.1	  	Company Indemnification.	  	27
		 	8.2	  	Purchaser’s Indemnification.	  	27
			
	9.	 	Exercise of Warrant.	  	27
		 	9.1	  	Mechanics of Exercise.	  	27
			
	10.	 	Registration Rights.	  	29
		 	10.1	  	Registration Rights Granted.	  	29
		 	10.2	  	Offering Restrictions.	  	29
			
	11.	 	Miscellaneous.	  	29
		 	11.1	  	Governing Law, Jurisdiction and Waiver of Jury Trial.	  	29
		 	11.2	  	Severability.	  	30
		 	11.3	  	Survival.	  	30
		 	11.4	  	Successors.	  	30
		 	11.5	  	Entire Agreement; Maximum Interest.	  	31
		 	11.6	  	Amendment and Waiver.	  	31
		 	11.7	  	Delays or Omissions.	  	31
		 	11.8	  	Notices.	  	31
		 	11.9	  	Attorneys’ Fees.	  	32
		 	11.10	  	Titles and Subtitles.	  	33
		 	11.11	  	Facsimile Signatures; Counterparts.	  	33
		 	11.12	  	Broker’s Fees.	  	33
		 	11.13	  	Construction.	  	33

  

 ii 








 LIST OF EXHIBITS 
  

			
	Form of Secured Promissory Note	  	Exhibit A
	Form of Warrant	  	Exhibit B
	Form of Escrow Agreement	  	Exhibit C

 LIST OF SCHEDULES 
  

			
	Subsidiary	  	Schedule 4.2
	Capital Stock of Company and Subsidiary	  	Schedule 4.3
	Agreements	  	Schedule 4.6
	Obligations to Related Parties	  	Schedule 4.7
	Title; liens	  	Schedule 4.9
	Litigation	  	Schedule 4.12
	Tax Returns and Payments	  	Schedule 4.13
	Employees	  	Schedule 4.14
	Registration Rights; Voting Rights	  	Schedule 4.15
	Environmental and Safety Laws	  	Schedule 4.17
	SEC Reports	  	Schedule 4.21
	Indebtedness	  	Schedule 6.12(I)(e)
	Debt Payment Obligations	  	Schedule 6.12(V)
	Broker’s Fees	  	Schedule 11.12

  

 iii 








 NOTE AND WARRANT PURCHASE AGREEMENT 
 THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 31, 2006, by and between BIOVEST
INTERNATIONAL, INC., a Delaware corporation (the “Company”), and LAURUS MASTER FUND, LTD., a Cayman Islands company (the “Purchaser”). 
 RECITALS 
 WHEREAS, the Company has authorized the sale to the Purchaser of a Secured Promissory Note
in the aggregate principal amount of Seven Million Seven Hundred Ninety-Nine Thousand and 00/100 Dollars ($7,799,000.00) in the form of Exhibit A hereto (as amended, modified and/or supplemented from time to time, the “Note”); 

WHEREAS, the Company wishes to issue to the Purchaser a warrant in the form of Exhibit B hereto (as amended, modified and/or supplemented from time to
time, the “Warrant”) to purchase up to 18,087,889 shares of the Company’s Common Stock (subject to adjustment as set forth therein) in connection with the Purchaser’s purchase of the Note; 
 WHEREAS, the Purchaser desires to purchase the Note and the Warrant on the terms and conditions set forth herein; and 
 WHEREAS, the Company desires to issue and sell the Note and Warrant to the Purchaser on the terms and conditions set forth herein. 
 AGREEMENT 
 NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual promises, representations, warranties and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows: 
 1. Agreement to Sell and Purchase. Pursuant to the terms and conditions set forth in this Agreement, on the
Closing Date (as defined in Section 3), the Company shall sell to the Purchaser, and the Purchaser shall purchase from the Company, the Note and the Warrant. The sale of the Note and the Warrant on the Closing Date shall be known as the
“Offering.” The Note will mature on the Maturity Date (as defined in the Note). Collectively, the Note and Warrant and Common Stock issuable upon exercise of the Warrant are referred to as the “Securities.” 
 2. Fees and Warrant. On the Closing Date: 
 (a) The Company will issue and deliver to the Purchaser the Warrant to purchase up to 18,087,889 shares of Common Stock (subject to adjustment as set forth therein) in connection with the Offering, pursuant to
Section 1 hereof. All the representations, covenants, warranties, undertakings, and indemnification, and other rights made or granted to or for the benefit of the Purchaser by the Company are hereby 







 also made and granted for the benefit of the holder of the Warrant and shares of the Company’s
Common Stock issuable upon exercise of the Warrant (the “Warrant Shares”). 
 (b) Subject to the terms of
Section 2(d) below, the Company shall pay to Laurus Capital Management, LLC, the manager of the Purchaser, a closing payment in an amount equal to Two Hundred Sixty-Two Thousand Five Hundred and 00/100 Dollars ($262,500). The foregoing fee is
referred to herein as the “Closing Payment.” 
 (c) The Company shall reimburse the Purchaser for its reasonable
expenses (including legal fees and expenses) incurred in connection with the preparation and negotiation of this Agreement and the Related Agreements (as hereinafter defined), and expenses incurred in connection with the Purchaser’s due
diligence review of the Company and its Subsidiaries (as defined in Section 4.2) and all related matters. Amounts required to be paid under this Section 2(c) will be paid on the Closing Date and shall be equal to the sum of
(x) $44,500 for such expenses referred to in this Section 2(c) plus (y) the cost of any required third-party appraisals and/or extraordinary diligence, subject to the Company’s prior approval plus (z) fees and
expenses of outside counsel to the extent the retention of same is deemed prudent by Laurus. 
 (d) The Closing Payment and
the expenses referred to in the preceding clause (c) (net of deposits previously paid by the Company) shall be paid at closing out of funds held pursuant to the Escrow Agreement (as defined below) and a disbursement letter (the
“Disbursement Letter”). 
 3. Closing, Delivery and Payment. 
 3.1 Closing. Subject to the terms and conditions herein, the closing of the transactions contemplated hereby (the “Closing”), shall take
place on the date hereof, at such time or place as the Company and the Purchaser may mutually agree (such date is hereinafter referred to as the “Closing Date”). 
 3.2 Delivery. Pursuant to the Escrow Agreement, at the Closing on the Closing Date, the Company will deliver to the Purchaser, among other things,
the Note and the Warrant and the Purchaser will deliver to the Company, among other things, the amounts set forth in the Disbursement Letter by certified funds or wire transfer (it being understood that $7,500,000 of the proceeds of the Note shall
be placed in the Restricted Account (as defined in the Restricted Account Agreement referred to below) and disbursed in accordance with the terms set forth in the Note). The Company hereby acknowledges and agrees that Purchaser’s obligation to
purchase the Note and Warrant from the Company on the Closing Date shall be contingent upon the satisfaction (or waiver by the Purchaser in its sole discretion) of the items and matters set forth in the closing checklist provided by the Purchaser to
the Company on or prior to the Closing Date. 
  

 2 








 4. Representations and Warranties of the Company. The Company hereby represents and warrants to
the Purchaser as follows 
 4.1 Organization, Good Standing and Qualification. Each of the Company and each of its Subsidiaries is a
corporation, partnership or limited liability company, as the case may be, duly organized, validly existing and in good standing under the laws of its jurisdiction of organization. Each of the Company and each of its Subsidiaries has the corporate,
limited liability company or partnership, as the case may be, power and authority to own and operate its properties and assets and, insofar as it is or shall be a party thereto, to (1) execute and deliver (i) this Agreement, (ii) the
Note and the Warrant to be issued in connection with this Agreement, (iii) the Master Security Agreement dated as of the date hereof between the Company and its Subsidiaries and the Purchaser (as amended, modified and/or supplemented from time
to time, the “Master Security Agreement”), (iv) the Stock Pledge Agreement dated as of the date hereof between the Company, the Company’s Subsidiaries and the Purchaser (as amended, modified and/or supplemented from time to time,
the “Stock Pledge Agreement”), (v) the Stock Pledge Agreement dated as of the date hereof between Accentia Biopharmaceuticals, Inc., a Florida corporation (“Accentia”) and the Purchaser (as amended, modified and/or
supplemented from time to time, the “Accentia Pledge Agreement”), (vi) the Registration Rights Agreement relating to the Securities dated as of the date hereof between the Company and the Purchaser (as amended, modified and/or
supplemented from time to time, the “Registration Rights Agreement”), (vii) the Guaranty dated as of the date hereof made by Accentia for the benefit of the Purchaser (as amended, modified and/or supplemented from time to time, the
“Parent Guaranty”), (viii) the Subsidiary Guaranty dated as of the date hereof made by the Subsidiaries of the Company for the benefit of the Purchaser (as amended, modified and/or supplemented from time to time, the “Subsidiary
Guaranty”), (ix) the Subordination Agreement dated as of the date hereof between the Parent, the Company and the Purchaser in form and substance reasonably satisfactory to the Purchaser (as amended, modified and/or supplemented from time
to time, the “Subordination Agreement”) in respect of all obligations owing by the Company to the Parent, now or in the future (the “Subordinated Obligations” and, together with all documentation related thereto, including
without limitation, all related security documentation, the “Subordinated Debt Documentation”), (x) the Funds Escrow Agreement dated as of the date hereof among the Company, the Purchaser and the escrow agent referred to therein,
substantially in the form of Exhibit C hereto (as amended, modified and/or supplemented from time to time, the “Escrow Agreement”), (xi) the Restricted Account Agreement dated as of the date hereof among the Company, the Purchaser and
North Fork Bank (as amended, modified or supplemented from time to time, the “Restricted Account Agreement”), (xii) the Restricted Account Side Letter related to the Restricted Account Agreement dated as of the date hereof between the
Company and the Purchaser (as amended, modified or supplemented from time to time, the “Restricted Account Side Letter”) and (xiii) all other documents, instruments and agreements entered into in connection with the transactions
contemplated hereby and thereby (the preceding clauses (ii) through (xii), collectively, the “Related Agreements”) (the preceding clauses (iii), (iv), (v), (vii) and (viii), together with each other security agreement, mortgage,
pledge and other similar agreements which are executed by the Company or any of its Subsidiaries in favor of the Purchaser, collectively, the “Security Documents”); (2) issue and sell the Note; (3) issue and sell the Warrant and
the Warrant Shares; and (4) carry out the provisions of this Agreement and the Related Agreements and to carry on its business as presently conducted. Each of the Company and each of its Subsidiaries is duly qualified and is authorized

  

 3 








 to do business and is in good standing as a foreign corporation, partnership or limited liability company, as the case
may be, in all jurisdictions in which the nature or location of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in which failure to do so has not, or could not
reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, liabilities, condition (financial or otherwise), properties, operations or prospects of the Company and its Subsidiaries, taken
individually and as a whole (a “Material Adverse Effect”). 
 4.2 Subsidiaries. Each direct and indirect Subsidiary of the
Company, the direct owner of such Subsidiary and its percentage ownership thereof, is set forth on Schedule 4.2. For the purpose of this Agreement, (x) a “Subsidiary” of any person or entity means (i) a corporation or other
entity whose shares of stock or other ownership interests having ordinary voting power (other than stock or other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the directors of such
corporation, or other persons or entities performing similar functions for such person or entity, are owned, directly or indirectly, by such person or entity or (ii) a corporation or other entity in which such person or entity owns, directly or
indirectly, more than 50% of the equity interests at such time and (y) a “Credit Party” means, the Company and each direct or indirect Subsidiary of the Company to the extent party to the Master Security Agreement, the Guaranty, the
Stock Pledge Agreement and such other security documentation required by the Purchaser to grant to the Purchaser a first priority perfected security interest in substantially all of such Subsidiary’s assets to secure the Obligations (as defined
in the Master Security Agreement). 
 4.3 Capitalization; Voting Rights. 
 (a) The authorized capital stock of the Company, as of the date hereof consists of 350,000,000 shares, of which 300,000,000 are shares of
Common Stock, par value $0.01 per share, 80,390,663 shares of which are issued and outstanding, and 50,000,000 are shares of preferred stock, par value $0.01 per share of which no shares of preferred stock are issued and outstanding. The authorized,
issued and outstanding capital stock of each Subsidiary of the Company is set forth on Schedule 4.3. 
 (b) Except as
disclosed on Schedule 4.3, other than: (i) the shares reserved for issuance under the Company’s stock option plans; and (ii) shares which may be granted pursuant to this Agreement and the Related Agreements, there are no outstanding
options, warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or stockholder agreements, or arrangements or agreements of any kind for the purchase or acquisition from the Company of any of its securities.
Except as disclosed on Schedule 4.3, neither the offer, issuance or sale of any of the Note or the Warrant, or the issuance of any of the Warrant Shares, nor the consummation of any transaction contemplated hereby will result in a change in the
price or number of any securities of the Company outstanding, under anti-dilution or other similar provisions contained in or affecting any such securities. 
 (c) All issued and outstanding shares of the Company’s Common Stock: (i) have been duly authorized and validly issued and are
fully paid and nonassessable; and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 
  

 4 








 (d) The rights, preferences, privileges and restrictions of the shares of the Common
Stock are as stated in the Company’s Certificate of Incorporation (the “Charter”). The Warrant Shares have been duly and validly reserved for issuance. When issued in compliance with the provisions of this Agreement and the
Company’s Charter, the Securities will be validly issued, fully paid and nonassessable, and will be free of any liens or encumbrances; provided, however, that the Securities may be subject to restrictions on transfer under state and/or federal
securities laws as set forth herein or as otherwise required by such laws at the time a transfer is proposed. 
 4.4 Authorization;
Binding Obligations. All corporate, partnership or limited liability company, as the case may be, action on the part of the Company and each of its Subsidiaries (including their respective officers and directors) necessary for the authorization
of this Agreement and the Related Agreements, the performance of all obligations of the Company and its Subsidiaries hereunder and under the other Related Agreements at the Closing and, the authorization, sale, issuance and delivery of the Note and
Warrant has been taken or will be taken prior to the Closing. This Agreement and the Related Agreements, when executed and delivered and to the extent it is a party thereto, will be valid and binding obligations of each of the Company and each of
its Subsidiaries, enforceable against each such person or entity in accordance with their terms, except: 
 (a) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights; and 
 (b) general principles of equity that restrict the availability of equitable or legal remedies. 
 The sale of the Note is
not and will not be subject to any preemptive rights or rights of first refusal that have not been properly waived or complied with. The issuance of the Warrant and the subsequent exercise of the Warrant for Warrant Shares are not and will not be
subject to any preemptive rights or rights of first refusal that have not been properly waived or complied with. 
 4.5 Liabilities.
Neither the Company nor any of its Subsidiaries has any liabilities, except current liabilities incurred in the ordinary course of business and liabilities disclosed in any of the Company’s filings under the Securities Exchange Act of 1934
(“Exchange Act”) made prior to the date of this Agreement (collectively, the “Exchange Act Filings”), copies of which have been provided to the Purchaser. 
 4.6 Agreements; Action. Except (i) as set forth on Schedule 4.6, (ii) for the convertible loan agreement between the Company and Telesis
CDE, LLC, a Delaware limited liability company (“Telesis”), and other CDE entities, (iii) grants, awards and other loans received by the Company from government and other municipalities, (iv) the convertible note from the Company
to Telesis and other CDEs evidencing the loan under the applicable convertible loan agreement, that certain securities purchase agreement between the Company and 
  

 5 








 Telesis and other CDEs, and any other agreements, documents and instruments executed in connection therewith (such
documents under subsection (ii), (iii) and (iv) as amended, modified or renewed from time to time, collectively, the “New Market Transactions Documents”), or (iv) as disclosed in any Exchange Act Filings: 
 (a) there are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or decrees to which
the Company or any of its Subsidiaries is a party or by which it is bound which may involve: (i) obligations (contingent or otherwise) of, or payments to, the Company or any of its Subsidiaries in excess of $50,000 (other than obligations of,
or payments to, the Company or any of its Subsidiaries arising from purchase or sale agreements entered into in the ordinary course of business); or (ii) the transfer or license of any patent, copyright, trade secret or other proprietary right
to or from the Company or any of its Subsidiaries (other than licenses arising from the purchase of “off the shelf” or other standard products); or (iii) provisions restricting the development, manufacture or distribution of the
Company’s or any of its Subsidiaries products or services; or (iv) indemnification by the Company or any of its Subsidiaries with respect to infringements of proprietary rights. 
 (b) Since September 30, 2005 (the “Balance Sheet Date”), neither the Company nor any of its Subsidiaries has, except in the
ordinary course of business: (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock; (ii) incurred any indebtedness for money borrowed or any other
liabilities (other than ordinary course obligations) individually in excess of $50,000 or, in the case of indebtedness and/or liabilities individually less than $50,000, in excess of $100,000 in the aggregate; (iii) made any loans or advances
to any person or entity not in excess, individually or in the aggregate, of $100,000, other than ordinary course advances for travel expenses; or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of
its inventory in the ordinary course of business. 
 (c) For the purposes of subsections (a) and (b) above, all
indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same person or entity (including persons or entities the Company or any Subsidiary of the Company has reason to believe are
affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections. 
 (d) The Company maintains disclosure controls and procedures (“Disclosure Controls”) designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”). 
 (e) The Company makes and keep books, records, and accounts, that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the 
  

 6 








 Company’s assets. The Company maintains internal control over financial reporting (“Financial
Reporting Controls”) designed by, or under the supervision of, the Company’s principal executive and principal financial officers, and effected by the Company’s board of directors, management, and other personnel, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (“GAAP”) as implemented by the SEC for
reporting companies, including that: 
 (i) transactions are executed in accordance with management’s general or specific
authorization; 
 (ii) unauthorized acquisition, use, or disposition of the Company’s assets that could have a material
effect on the financial statements are prevented or timely detected; 
 (iii) transactions are recorded as necessary to permit
preparation of financial statements in accordance with GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s management and board of directors; 
 (iv) transactions are recorded as necessary to maintain accountability for assets; and 
 (v) the recorded accountability for assets is compared with the existing assets at reasonable intervals, and appropriate action is taken
with respect to any differences. 
 (f) There is no weakness in any of the Company’s Disclosure Controls or Financial
Reporting Controls that is required to be disclosed in any of the Exchange Act Filings, except as so disclosed. 
 4.7 Obligations to
Related Parties. Except as set forth on Schedule 4.7, there are no obligations of the Company or any of its Subsidiaries to officers, directors, stockholders or employees of the Company or any of its Subsidiaries other than: 
 (a) for payment of salary for services rendered and for bonus payments; 
 (b) reimbursement for reasonable expenses incurred on behalf of the Company and its Subsidiaries; 
 (c) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under
any stock option plan approved by the Board of Directors of the Company and each Subsidiary of the Company, as applicable); and 
 (d) obligations listed in the Company’s and each of its Subsidiary’s financial statements or disclosed in any of the Company’s Exchange Act Filings. 
  

 7 








 Except as described above or set forth on Schedule 4.7, none of the officers, directors or, to the best of the
Company’s knowledge, key employees or stockholders of the Company or any of its Subsidiaries or any members of their immediate families, are indebted to the Company or any of its Subsidiaries, individually or in the aggregate, in excess of
$50,000 or have any direct or indirect ownership interest in any firm or corporation with which the Company or any of its Subsidiaries is affiliated or with which the Company or any of its Subsidiaries has a business relationship, or any firm or
corporation which competes with the Company or any of its Subsidiaries, other than passive investments in publicly traded companies (representing less than one percent (1%) of such company) which may compete with the Company or any of its
Subsidiaries. Except as described above, no officer, director or stockholder of the Company or any of its Subsidiaries, or any member of their immediate families, is, directly or indirectly, interested in any material contract with the Company or
any of its Subsidiaries and no agreements, understandings or proposed transactions are contemplated between the Company or any of its Subsidiaries and any such person. Except as set forth on Schedule 4.7, neither the Company nor any of its
Subsidiaries is a guarantor or indemnitor of any indebtedness of any other person or entity. 
 4.8 Changes. Since the Balance Sheet
Date, except as disclosed in any Exchange Act Filing or in any Schedule to this Agreement or to any of the Related Agreements, there has not been: 
 (a) except for additional loan disbursements by the Parent to the Company under those certain demand notes issued by the Company to the Parent (the “Parent Disbursements”), any change in the business,
assets, liabilities, condition (financial or otherwise), properties, operations or prospects of the Company or any of its Subsidiaries, which individually or in the aggregate has had, or could reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect; 
 (b) any resignation or termination of any officer, key employee or group of employees
of the Company or any of its Subsidiaries; 
 (c) except for the Parent Disbursements, any material change, except in the
ordinary course of business, in the contingent obligations of the Company or any of its Subsidiaries by way of guaranty, endorsement, indemnity, warranty or otherwise; 
 (d) any damage, destruction or loss, whether or not covered by insurance, which has had, or could reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect; 
 (e) any waiver by the Company or any of its Subsidiaries of a
valuable right or of a material debt owed to it; 
 (f) any direct or indirect loans made by the Company or any of its
Subsidiaries to any stockholder, employee, officer or director of the Company or any of its Subsidiaries, other than advances made in the ordinary course of business; 
 (g) any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder of the Company or
any of its Subsidiaries; 
  

 8 








 (h) any declaration or payment of any dividend or other distribution of the assets of the
Company or any of its Subsidiaries; 
 (i) any labor organization activity related to the Company or any of its Subsidiaries;

 (j) any debt, obligation or liability incurred, assumed or guaranteed by the Company or any of its Subsidiaries, except for
(i) the Parent Disbursements, and (ii) those immaterial amounts and for current liabilities incurred in the ordinary course of business; 
 (k) any sale, assignment or transfer of any patents, trademarks, copyrights, trade secrets or other intangible assets owned by the Company or any of its Subsidiaries; 
 (l) any change in any material agreement to which the Company or any of its Subsidiaries is a party or by which either the Company or any
of its Subsidiaries is bound which either individually or in the aggregate has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; 
 (m) any other event or condition of any character that, either individually or in the aggregate, has had, or could reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect; or 
 (n) any arrangement or commitment by the Company
or any of its Subsidiaries to do any of the acts described in subsection (a) through (m) above. 
 4.9 Title to Properties and
Assets; Liens, Etc. Except as set forth on Schedule 4.9, each of the Company and each of its Subsidiaries has good and marketable title to its properties and assets, and good title to its leasehold interests, in each case subject to no
mortgage, pledge, lien, lease, encumbrance or charge, other than: 
 (a) those resulting from taxes which have not yet become
delinquent; 
 (b) minor liens and encumbrances which do not materially detract from the value of the property subject thereto
or materially impair the operations of the Company or any of its Subsidiaries, so long as in each such case, such liens and encumbrances have no effect on the lien priority of the Purchaser in such property; and 
 (c) those that have otherwise arisen in the ordinary course of business, so long as they have no effect on the lien priority of the
Purchaser therein. 
 All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company and its Subsidiaries
are in good operating condition and repair and are reasonably fit and usable for the purposes for which they are being used. Except as set forth on Schedule 4.9, the Company and its Subsidiaries are in compliance with all material terms of each
lease to which it is a party or is otherwise bound. 
  

 9 








 4.10 Intellectual Property. 
 (a) Each of the Company and each of its Subsidiaries owns or possesses sufficient legal rights to all patents, trademarks, service marks,
trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted and, to the Company’s knowledge, as presently proposed to be conducted (the “Intellectual
Property”), without any known infringement of the rights of others. There are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary rights, nor is the Company or any of its Subsidiaries bound by or a
party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other person or entity
other than such licenses or agreements arising from the purchase of “off the shelf” or standard products. 
 (b)
Neither the Company nor any of its Subsidiaries has received any communications alleging that the Company or any of its Subsidiaries has violated any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other
proprietary rights of any other person or entity, nor is the Company or any of its Subsidiaries aware of any basis therefor. 
 (c) The Company does not believe it is or will be necessary to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to their employment by the Company or any of its Subsidiaries, except for
inventions, trade secrets or proprietary information that have been rightfully assigned to the Company or any of its Subsidiaries. 
 4.11
Compliance with Other Instruments. Neither the Company nor any of its Subsidiaries is in violation or default of (x) any term of its Charter or Bylaws, or (y) any provision of any indebtedness, mortgage, indenture, contract,
agreement or instrument to which it is party or by which it is bound or of any judgment, decree, order or writ, which violation or default, in the case of this clause (y), has had, or could reasonably be expected to have, either individually or in
the aggregate, a Material Adverse Effect. The execution, delivery and performance of and compliance with this Agreement and the Related Agreements to which it is a party, and the issuance and sale of the Note by the Company and the other Securities
by the Company each pursuant hereto and thereto, will not, with or without the passage of time or giving of notice, result in any such material violation, or be in conflict with or constitute a default under any such term or provision, or result in
the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or any of its Subsidiaries or the suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license,
authorization or approval applicable to the Company, its business or operations or any of its assets or properties. 
 4.12
Litigation. Except as set forth on Schedule 4.12 hereto, there is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened against the Company or any of its Subsidiaries that prevents the
Company or any of its Subsidiaries from entering into this Agreement or the other Related Agreements, or from 
  

 10 








 consummating the transactions contemplated hereby or thereby, or which has had, or could reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect or any change in the current equity ownership of the Company or any of its Subsidiaries, nor is the Company aware that there is any basis to assert any of the foregoing. Neither the
Company nor any of its Subsidiaries is a party to or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the
Company or any of its Subsidiaries currently pending or which the Company or any of its Subsidiaries intends to initiate. 
 4.13 Tax
Returns and Payments. Each of the Company and each of its Subsidiaries has timely filed all tax returns (federal, state and local) required to be filed by it. All taxes shown to be due and payable on such returns, any assessments imposed, and
all other taxes due and payable by the Company or any of its Subsidiaries on or before the Closing, have been paid or will be paid prior to the time they become delinquent. Except as set forth on Schedule 4.13, neither the Company nor any of
its Subsidiaries has been advised: 
 (a) that any of its returns, federal, state or other, have been or are being audited as
of the date hereof; or 
 (b) of any adjustment, deficiency, assessment or court decision in respect of its federal, state or
other taxes. 
 The Company has no knowledge of any liability for any tax to be imposed upon its properties or assets as of the date of this Agreement that
is not adequately provided for. 
 4.14 Employees. Except as set forth on Schedule 4.14, neither the Company nor any of its
Subsidiaries has any collective bargaining agreements with any of its employees. There is no labor union organizing activity pending or, to the Company’s knowledge, threatened with respect to the Company or any of its Subsidiaries. Except as
disclosed in the Exchange Act Filings or on Schedule 4.14, neither the Company nor any of its Subsidiaries is a party to or bound by any currently effective employment contract, deferred compensation arrangement, bonus plan, incentive plan, profit
sharing plan, retirement agreement or other employee compensation plan or agreement. To the Company’s knowledge, no employee of the Company or any of its Subsidiaries, nor any consultant with whom the Company or any of its Subsidiaries has
contracted, is in violation of any term of any employment contract, proprietary information agreement or any other agreement relating to the right of any such individual to be employed by, or to contract with, the Company or any of its Subsidiaries
because of the nature of the business to be conducted by the Company or any of its Subsidiaries; and to the Company’s knowledge the continued employment by the Company and its Subsidiaries of their present employees, and the performance of the
Company’s and its Subsidiaries’ contracts with its independent contractors, will not result in any such violation. Neither the Company nor any of its Subsidiaries is aware that any of its employees is obligated under any contract
(including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency that would interfere with their duties to the Company or any of its Subsidiaries.
Neither the Company nor any of its Subsidiaries has received any notice alleging that any such violation has occurred. Except for employees who have a current effective employment agreement with the Company or any of its Subsidiaries, no employee of
the 
  

 11 








 Company or any of its Subsidiaries has been granted the right to continued employment by the Company or any of its
Subsidiaries or to any material compensation following termination of employment with the Company or any of its Subsidiaries. Except as set forth on Schedule 4.14, the Company is not aware that any officer, key employee or group of employees intends
to terminate his, her or their employment with the Company or any of its Subsidiaries, nor does the Company or any of its Subsidiaries have a present intention to terminate the employment of any officer, key employee or group of employees.

 4.15 Registration Rights and Voting Rights. Except as set forth on Schedule 4.15 and except as disclosed in Exchange Act
Filings, neither the Company nor any of its Subsidiaries is presently under any obligation, and neither the Company nor any of its Subsidiaries has granted any rights, to register any of the Company’s or its Subsidiaries’ presently
outstanding securities or any of its securities that may hereafter be issued. Except as set forth on Schedule 4.15 and except as disclosed in Exchange Act Filings, to the Company’s knowledge, no stockholder of the Company or any of its
Subsidiaries has entered into any agreement with respect to the voting of equity securities of the Company or any of its Subsidiaries. 
 4.16 Compliance with Laws; Permits. Neither the Company nor any of its Subsidiaries is in violation of any provision of the Sarbanes-Oxley Act of 2002 or any SEC related regulation or rule or any rule of the Principal Market (as
hereafter defined) promulgated thereunder or any other applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the
ownership of its properties which has had, or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. No governmental orders, permissions, consents, approvals or authorizations are required to be
obtained and no registrations or declarations are required to be filed in connection with the execution and delivery of this Agreement or any other Related Agreement and the issuance of any of the Securities, except such as have been duly and
validly obtained or filed, or with respect to any filings that must be made after the Closing, as will be filed in a timely manner. Each of the Company and its Subsidiaries has all material franchises, permits, licenses and any similar authority
necessary for the conduct of its business as now being conducted by it, the lack of which could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 4.17 Environmental and Safety Laws. Neither the Company nor any of its Subsidiaries is in violation of any applicable statute, law or regulation
relating to the environment or occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. Except as set forth on Schedule 4.17, no
Hazardous Materials (as defined below) are used or have been used, stored, or disposed of by the Company or any of its Subsidiaries or, to the Company’s knowledge, by any other person or entity on any property owned, leased or used by the
Company or any of its Subsidiaries. For the purposes of the preceding sentence, “Hazardous Materials” shall mean: 
 (a) materials which are listed or otherwise defined as “hazardous” or “toxic” under any applicable local, state, federal and/or foreign laws and regulations that govern the existence and/or remedy of contamination on
property, the protection of the environment from contamination, the control of hazardous wastes, or other activities involving hazardous substances, including building materials; or 
  

 12 








 (b) any petroleum products or nuclear materials. 
 4.18 Valid Offering. Assuming the accuracy of the representations and warranties of the Purchaser contained in this Agreement, the offer, sale and
issuance of the Securities will be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and will have been registered or qualified (or are exempt from registration and qualification)
under the registration, permit or qualification requirements of all applicable state securities laws. 
 4.19 Full Disclosure. Each of
the Company and each of its Subsidiaries has provided the Purchaser with all publicly available information requested by the Purchaser in connection with its decision to purchase the Note and Warrant, including all information the Company and its
Subsidiaries believe is reasonably necessary to make such investment decision. Neither this Agreement, the Related Agreements, the exhibits and schedules hereto and thereto nor any other document delivered by the Company or any of its Subsidiaries
to Purchaser or its attorneys or agents in connection herewith or therewith or with the transactions contemplated hereby or thereby, contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the
statements contained herein or therein, in light of the circumstances in which they are made, not misleading. Any financial projections and other estimates provided to the Purchaser by the Company or any of its Subsidiaries were based on the
Company’s and its Subsidiaries’ experience in the industry and on assumptions of fact and opinion as to future events which the Company or any of its Subsidiaries, at the date of the issuance of such projections or estimates, believed to
be reasonable. 
 4.20 Insurance. Each of the Company and each of its Subsidiaries has general commercial, product liability, fire and
casualty insurance policies with coverages which the Company believes are customary for companies similarly situated to the Company and its Subsidiaries in the same or similar business. 
 4.21 SEC Reports. Except as set forth on Schedule 4.21, the Company has filed all proxy statements, reports and other documents required to be
filed by it under the Securities Exchange Act 1934, as amended (the “Exchange Act”). The Company has furnished the Purchaser copies of: (i) its Annual Reports on Form 10-KSB for its fiscal year ended September 30, 2005; and
(ii) its Quarterly Reports on Form 10-QSB for its fiscal quarter ended December 31, 2005, and the Form 8-K filings which it has made during the fiscal year 2006 to date (collectively, the “SEC Reports”). Except as set forth on
Schedule 4.21, each SEC Report was, at the time of its filing, in substantial compliance with the requirements of its respective form and none of the SEC Reports, nor the financial statements (and the notes thereto) included in the SEC Reports, as
of their respective filing dates, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading. 
  

 13 








 4.22 Listing. The Company’s Common Stock is listed or quoted, as applicable, on a Principal
Market (as hereafter defined) and satisfies and at all times hereafter will satisfy, all requirements for the continuation of such listing or quotation, as applicable. The Company has not received any notice that its Common Stock will be delisted
from, or no longer quoted on, as applicable, the Principal Market or that its Common Stock does not meet all requirements for such listing or quotation, as applicable. For purposes hereof, the term “Principal Market” means the NASD Over
The Counter Bulletin Board, NASDAQ Capital Market, NASDAQ National Markets System, American Stock Exchange or New York Stock Exchange (whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock).

 4.23 No Integrated Offering. Neither the Company, nor any of its Subsidiaries or affiliates, nor any person acting on its or their
behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the Securities pursuant to this Agreement or any of the Related Agreements
to be integrated with prior offerings by the Company for purposes of the Securities Act which would prevent the Company from selling the Securities pursuant to Rule 506 under the Securities Act, or any applicable exchange-related stockholder
approval provisions, nor will the Company or any of its affiliates or Subsidiaries take any action or steps that would cause the offering of the Securities to be integrated with other offerings. 
 4.24 Stop Transfer. The Securities are restricted securities as of the date of this Agreement. Neither the Company nor any of its Subsidiaries
will issue any stop transfer order or other order impeding the sale and delivery of any of the Securities at such time as the Securities are registered for public sale or an exemption from registration is available, except as required by state and
federal securities laws. 
 4.25 Dilution. The Company specifically acknowledges that its obligation to issue the shares of Common
Stock upon exercise of the Warrant is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other shareholders of the Company. 
 4.26 Patriot Act. The Company certifies that, to the best of Company’s knowledge, neither the Company nor any of its Subsidiaries has been
designated, nor is or shall be owned or controlled, by a “suspected terrorist” as defined in Executive Order 13224. The Company hereby acknowledges that the Purchaser seeks to comply with all applicable laws concerning money laundering and
related activities. In furtherance of those efforts, the Company hereby represents, warrants and covenants that: (i) none of the cash or property that the Company or any of its Subsidiaries will pay or will contribute to the Purchaser has been
or shall be derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no contribution or payment by the Company or any of its Subsidiaries to the Purchaser, to the extent that they are within the
Company’s and/or its Subsidiaries’ control shall cause the Purchaser to be in violation of the United States Bank Secrecy Act, the United States International Money Laundering Control Act of 1986 or the United States International Money
Laundering Abatement and Anti-Terrorist Financing Act of 2001. The Company shall promptly notify the Purchaser if any of these representations, warranties or covenants ceases to be true and accurate regarding the Company or any of its Subsidiaries.
The Company shall provide the Purchaser all additional information regarding the Company or any of its Subsidiaries that the 
  

 14 








 Purchaser deems necessary or convenient to ensure compliance with all applicable laws concerning money laundering and
similar activities. The Company understands and agrees that if at any time it is discovered that any of the foregoing representations, warranties or covenants are incorrect, or if otherwise required by applicable law or regulation related to money
laundering or similar activities, the Purchaser may undertake appropriate actions to ensure compliance with applicable law or regulation, including but not limited to segregation and/or redemption of the Purchaser’s investment in the Company.
The Company further understands that the Purchaser may release confidential information about the Company and its Subsidiaries and, if applicable, any underlying beneficial owners, to proper authorities if the Purchaser, in its sole discretion,
determines that it is in the best interests of the Purchaser in light of relevant rules and regulations under the laws set forth in subsection (ii) above. 
 4.27 ERISA. Based upon the Employee Retirement Income Security Act of 1974 (“ERISA”), and the regulations and published interpretations thereunder: (i) neither the Company nor any of its
Subsidiaries has engaged in any Prohibited Transactions (as defined in Section 406 of ERISA and Section 4975 of the Internal Revenue Code of 1986, as amended (the “Code”)); (ii) each of the Company and each of its
Subsidiaries has met all applicable minimum funding requirements under Section 302 of ERISA in respect of its plans; (iii) neither the Company nor any of its Subsidiaries has any knowledge of any event or occurrence which would cause the
Pension Benefit Guaranty Corporation to institute proceedings under Title IV of ERISA to terminate any employee benefit plan(s); (iv) neither the Company nor any of its Subsidiaries has any fiduciary responsibility for investments with respect
to any plan existing for the benefit of persons other than the Company’s or such Subsidiary’s employees; and (v) neither the Company nor any of its Subsidiaries has withdrawn, completely or partially, from any multi-employer pension
plan so as to incur liability under the Multiemployer Pension Plan Amendments Act of 1980. 
 5. Representations and Warranties of the
Purchaser. The Purchaser hereby represents and warrants to the Company as follows (such representations and warranties do not lessen or obviate the representations and warranties of the Company set forth in this Agreement): 
 5.1 Incorporation; No Shorting. The Purchaser is a company validly existing and in good standing under the laws of the Cayman Islands and has no
offices in the State of New York. The Purchaser or any of its affiliates and investment partners has not, will not and will not cause any person or entity, to directly engage in “short sales” of the Company’s Common Stock as long as
the Note shall be outstanding. 
 5.2 Requisite Power and Authority. The Purchaser has all necessary power and authority under all
applicable provisions of law to execute and deliver this Agreement and the Related Agreements and to carry out their provisions. All corporate action on the Purchaser’s part required for the lawful execution and delivery of this Agreement and
the Related Agreements have been or will be effectively taken prior to the Closing. Upon their execution and delivery, this Agreement and the Related Agreements will be valid and binding obligations of the Purchaser, enforceable in accordance with
their terms, except: 
 (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of
general application affecting enforcement of creditors’ rights; and 
  

 15 








 (b) as limited by general principles of equity that restrict the availability of
equitable and legal remedies. 
 5.3 Investment Representations. The Purchaser understands that the Securities are being offered and
sold pursuant to an exemption from registration contained in the Securities Act based in part upon the Purchaser’s representations contained in this Agreement, including, without limitation, that the Purchaser is an “accredited
investor” within the meaning of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The Purchaser confirms that it has received or has had full access to all the information it considers necessary or
appropriate to make an informed investment decision with respect to the Note and the Warrant to be purchased by it under this Agreement and the Warrant Shares acquired by it upon the exercise of the Warrant, respectively. The Purchaser further
confirms that it has had an opportunity to ask questions and receive answers from the Company regarding the Company’s and its Subsidiaries’ business, management and financial affairs and the terms and conditions of the Offering, the Note,
the Warrant and the Securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the Purchaser or
to which the Purchaser had access. 
 5.4 The Purchaser Bears Economic Risk. The Purchaser has substantial experience in evaluating
and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. The
Purchaser must bear the economic risk of this investment until the Securities are sold pursuant to: (i) an effective registration statement under the Securities Act; or (ii) an exemption from registration is available with respect to such
sale. 
 5.5 Acquisition for Own Account. The Purchaser is acquiring the Note and Warrant and the Warrant Shares for the
Purchaser’s own account for investment only, and not as a nominee or agent and not with a view towards or for resale in connection with their distribution. 
 5.6 The Purchaser Can Protect Its Interest. The Purchaser represents that by reason of its, or of its management’s, business and financial experience, the Purchaser has the capacity to evaluate the merits
and risks of its investment in the Note, the Warrant and the Securities and to protect its own interests in connection with the transactions contemplated in this Agreement and the Related Agreements. Further, the Purchaser is aware of no publication
of any advertisement in connection with the transactions contemplated in the Agreement or the Related Agreements. 
 5.7 Accredited
Investor. The Purchaser represents that it is an accredited investor within the meaning of Regulation D under the Securities Act. 
  

 16 








 5.8 Legends. 
 (a) The Warrant Shares shall bear a legend which shall be in substantially the following form until such shares are covered by an
effective registration statement filed with the SEC: 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND APPLICABLE STATE
LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO BIOVEST INTERNATIONAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 (b) The Warrant shall bear substantially the following legend: 
 “THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF
THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT OR THE UNDERLYING SHARES OF COMMON STOCK UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO BIOVEST
INTERNATIONAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 6. Covenants of the Company. The Company covenants and agrees
with the Purchaser as follows: 
 6.1 Stop-Orders. The Company will advise the Purchaser, promptly after it receives notice of issuance
by the SEC, any state securities commission or any other regulatory authority of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension of the qualification of the Common Stock of
the Company for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose. 
 6.2 Listing. The
Company shall maintain its listing or quotation, as applicable, of the shares of Common Stock issuable upon the exercise of the Warrant on the Principal Market upon which shares of Common Stock are listed or quoted for trading, as applicable
(subject to official notice of issuance, so long as any other shares of Common Stock shall be so listed or quoted, as applicable. The Company shall maintain the listing or quotation, as applicable, of its Common Stock on the Principal Market, and
shall comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable. 
  

 17 








 6.3 Market Regulations. The Company shall notify the SEC, NASD and applicable state authorities,
in accordance with their requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation, for the legal and valid
issuance of the Securities to the Purchaser and promptly provide copies thereof to the Purchaser. 
 6.4 Reporting Requirements. The
Company will deliver, or cause to be delivered, to the Purchaser each of the following, which shall be in form and detail acceptable to the Purchaser: 
 (a) As soon as available, and in any event within ninety (90) days after the end of each fiscal year of the Company, each of the Company’s and each of its Subsidiaries’ audited financial statements with
a report of independent certified public accountants of recognized standing selected by the Company (the “Accountants”), which annual financial statements shall be without qualification and shall include each of the Company’s
and each of its Subsidiaries’ balance sheet as at the end of such fiscal year and the related statements of each of the Company’s and each of its Subsidiaries’ income, retained earnings and cash flows for the fiscal year then ended,
prepared on a consolidating and consolidated basis to include the Company, each Subsidiary of the Company and each of their respective affiliates, all in reasonable detail and prepared in accordance with GAAP, together with (i) if and when
available, copies of any management letters prepared by the Accountants; and (ii) a certificate of the Company’s President, Chief Executive Officer or Chief Financial Officer stating that such financial statements have been prepared in
accordance with GAAP and whether or not such officer has knowledge of the occurrence of any Event of Default (as defined in the Note) and, if so, stating in reasonable detail the facts with respect thereto; 
 (b) As soon as available and in any event within forty five (45) days after the end of each fiscal quarter of the Company, an
unaudited/internal balance sheet and statements of income, retained earnings and cash flows of the Company and each of its Subsidiaries as at the end of and for such quarter and for the year to date period then ended, prepared on a consolidating and
consolidated basis to include all the Company, each Subsidiary of the Company and each of their respective affiliates, in reasonable detail and stating in comparative form the figures for the corresponding date and periods in the previous year, all
prepared in accordance with GAAP, subject to year-end adjustments and accompanied by a certificate of the Company’s President, Chief Executive Officer or Chief Financial Officer, stating (i) that such financial statements have been
prepared in accordance with GAAP, subject to year-end audit adjustments, and (ii) whether or not such officer has knowledge of the occurrence of any Event of Default (as defined in the Note) not theretofore reported and remedied and, if so,
stating in reasonable detail the facts with respect thereto; 
 (c) As soon as available and in any event within fifteen
(15) days after the end of each calendar month, an unaudited/internal balance sheet and statements of income, 
  

 18 








 retained earnings and cash flows of each of the Company and its Subsidiaries as at the end of and for
such month and for the year to date period then ended, prepared on a consolidating and consolidated basis to include the Company, each Subsidiary of the Company and each of their respective affiliates, in reasonable detail and stating in comparative
form the figures for the corresponding date and periods in the previous year, all prepared in accordance with GAAP, subject to year-end adjustments and accompanied by a certificate of the Company’s President, Chief Executive Officer or Chief
Financial Officer, stating (i) that such financial statements have been prepared in accordance with GAAP, subject to year-end audit adjustments, and (ii) whether or not such officer has knowledge of the occurrence of any Event of Default
(as defined in the Note) not theretofore reported and remedied and, if so, stating in reasonable detail the facts with respect thereto; 
 (d) The Company shall timely file with the SEC all reports required to be filed pursuant to the Exchange Act and refrain from terminating its status as an issuer required by the Exchange Act to file reports thereunder
even if the Exchange Act or the rules or regulations thereunder would permit such termination. Promptly after (i) the filing thereof, copies of the Company’s most recent registration statements and annual, quarterly, monthly or other
regular reports which the Company files with the Securities and Exchange Commission (the “SEC”), and (ii) the issuance thereof, copies of such financial statements, reports and proxy statements as the Company shall send to its
stockholders; and 
 (e) The Company shall deliver, or cause the applicable Subsidiary of the Company to deliver, such other
information as the Purchaser shall reasonably request. 
 6.5 Use of Funds. The Company shall use the proceeds of the sale of the Note
and the Warrant for general working capital purposes only, including but not limited to the New Market Transactions and the redemption of Company Common Stock held by Accentia Biopharmaceuticals, Inc. (it being understood that $7,500,000 of the
proceeds of the Note will be deposited in the Restricted Account on the Closing Date and shall be subject to the terms and conditions of the Restricted Account Agreement and the Restricted Account Side Letter). 
 6.6 Access to Facilities. Each of the Company and each of its Subsidiaries will permit any representatives designated by the Purchaser (or any
successor of the Purchaser), upon reasonable notice and during normal business hours, at such person’s expense and accompanied by a representative of the Company or any Subsidiary (provided that no such prior notice shall be required to be
given and no such representative of the Company or any Subsidiary shall be required to accompany the Purchaser in the event the Purchaser believes such access is necessary to preserve or protect the Collateral (as defined in the Master Security
Agreement) or following the occurrence and during the continuance of an Event of Default (as defined in the Note)), to: 
 (a)
visit and inspect any of the properties of the Company or any of its Subsidiaries; 
  

 19 








 (b) examine the corporate and financial records of the Company or any of its Subsidiaries
(unless such examination is not permitted by federal, state or local law or by contract) and make copies thereof or extracts therefrom; and 
 (c) discuss the affairs, finances and accounts of the Company or any of its Subsidiaries with the directors, officers and independent accountants of the Company or any of its Subsidiaries. 
 Notwithstanding the foregoing, neither the Company nor any of its Subsidiaries will provide any material, non-public information to the Purchaser unless the Purchaser
signs a confidentiality agreement and otherwise complies with Regulation FD, under the federal securities laws. 
 6.7 Taxes. Each of
the Company and each of its Subsidiaries will promptly pay and discharge, or cause to be paid and discharged, when due and payable, all taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business of
the Company and its Subsidiaries; provided, however, that any such tax, assessment, charge or levy need not be paid currently if (i) the validity thereof shall currently and diligently be contested in good faith by appropriate proceedings,
(ii) such tax, assessment, charge or levy shall have no effect on the lien priority of the Purchaser in any property of the Company or any of its Subsidiaries and (iii) if the Company and/or such Subsidiary shall have set aside on its
books adequate reserves with respect thereto in accordance with GAAP; and provided, further, that the Company and its Subsidiaries will pay all such taxes, assessments, charges or levies forthwith upon the commencement of proceedings to foreclose
any lien which may have attached as security therefor. 
 6.8 Insurance. Each of the Company and its Subsidiaries will keep its assets
which are of an insurable character insured by financially sound and reputable insurers against loss or damage by fire, explosion and other risks customarily insured against by companies in similar business similarly situated as the Company and its
Subsidiaries; and the Company and its Subsidiaries will maintain, with financially sound and reputable insurers, insurance against other hazards and risks and liability to persons and property to the extent and in the manner which the Company
reasonably believes is customary for companies in similar business similarly situated as the Company and its Subsidiaries and to the extent available on commercially reasonable terms. The Company, and each of its Subsidiaries, will jointly and
severally bear the full risk of loss from any loss of any nature whatsoever with respect to the assets pledged to the Purchaser as security for their respective obligations hereunder and under the Related Agreements. At the Company’s and each
of its Subsidiaries’ joint and several cost and expense in amounts and with carriers reasonably acceptable to the Purchaser, each of the Company and each of its Subsidiaries shall (i) keep all its insurable properties and properties in
which it has an interest insured against the hazards of fire, flood, sprinkler leakage, those hazards covered by extended coverage insurance and such other hazards, and for such amounts, as is customary in the case of companies engaged in businesses
similar to the Company’s or the respective Subsidiary’s including business interruption insurance; (ii) maintain a bond in such amounts as is customary in the case of companies engaged in businesses similar to the Company’s or
the respective Subsidiary’s insuring against larceny, embezzlement or other criminal misappropriation of insured’s officers and employees who may either singly or jointly with others at any time have access to the assets or funds of the
Company or any of its Subsidiaries either directly or through 
  

 20 








 governmental authority to draw upon such funds or to direct generally the disposition of such assets; (iii) maintain
public and product liability insurance against claims for personal injury, death or property damage suffered by others; (iv) maintain all such worker’s compensation or similar insurance as may be required under the laws of any state or
jurisdiction in which the Company or the respective Subsidiary is engaged in business; and (v) furnish the Purchaser with (x) copies of all policies and evidence of the maintenance of such policies at least thirty (30) days before any
expiration date, (y) excepting the Company’s workers’ compensation policy, endorsements to such policies naming the Purchaser as “co-insured” or “additional insured” and appropriate loss payable endorsements in
form and substance satisfactory to the Purchaser, naming the Purchaser as loss payee, and (z) evidence that as to the Purchaser the insurance coverage shall not be impaired or invalidated by any act or neglect of the Company or any Subsidiary
and the insurer will provide the Purchaser with at least thirty (30) days notice prior to cancellation. The Company and each Subsidiary shall instruct the insurance carriers that in the event of any loss thereunder, the carriers shall make
payment for such loss to the Company and/or the Subsidiary and the Purchaser jointly. In the event that as of the date of receipt of each loss recovery upon any such insurance, the Purchaser has not declared an event of default with respect to this
Agreement or any of the Related Agreements, then the Company and/or such Subsidiary shall be permitted to direct the application of such loss recovery proceeds toward investment in property, plant and equipment that would comprise
“Collateral” secured by the Purchaser’s security interest pursuant to the Master Security Agreement or such other security agreement as shall be required by the Purchaser, with any surplus funds to be applied toward payment of the
obligations of the Company to the Purchaser. In the event that the Purchaser has properly declared an event of default with respect to this Agreement or any of the Related Agreements, then all loss recoveries received by the Purchaser upon any such
insurance thereafter may be applied to the obligations of the Company hereunder and under the Related Agreements, in such order as the Purchaser may determine. Any surplus (following satisfaction of all Company obligations to the Purchaser) shall be
paid by the Purchaser to the Company or applied as may be otherwise required by law. Any deficiency thereon shall be paid by the Company or the Subsidiary, as applicable, to the Purchaser, on demand. 
 6.9 Intellectual Property. Each of the Company and each of its Subsidiaries shall maintain in full force and effect its existence, rights and
franchises and all licenses and other rights to use Intellectual Property owned or possessed by it and reasonably deemed to be necessary to the conduct of its business. 
 6.10 Properties. Each of the Company and each of its Subsidiaries will keep its properties in good repair, working order and condition, reasonable wear and tear excepted, and from time to time make all needful
and proper repairs, renewals, replacements, additions and improvements thereto; and each of the Company and each of its Subsidiaries will at all times comply with each provision of all leases to which it is a party or under which it occupies
property if the breach of such provision could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 6.11 Confidentiality. The Company will not, and will not permit any of its Subsidiaries to, disclose, and will not include in any public announcement, the name of the Purchaser, unless expressly agreed to by the Purchaser or unless
and until such disclosure is required by law or applicable regulation, and then only to the extent of such requirement. Notwithstanding the foregoing, the Company may disclose the Purchaser’s identity and the terms of this Agreement to its
current and prospective debt and equity financing sources. 
  

 21 








 6.12 Required Approvals. (I) For so long as twenty-five percent (25%) of the principal
amount of the Note is outstanding, the Company, without the prior written consent of the Purchaser, shall not, and shall not permit any of its Subsidiaries to: 
 (a) (i) directly or indirectly declare or pay any dividends, other than dividends paid to the Company or any other Credit Party,
(ii) issue any preferred stock that is manditorily redeemable prior to the earlier to occur of (x) the six month anniversary of the Maturity Date (as defined in the Note) and (y) the date upon which all Obligations (as defined in the
Master Security Agreement) of the Company and its Subsidiaries (as defined in the Master Security Agreement) arising under this Agreement and/or the Related Agreements shall have been indefeasibly satisfied in full or (iii) redeem any of its
preferred stock or other equity interests; 
 (b) liquidate, dissolve or effect a material reorganization (it being understood
that in no event shall the Company or any of its Subsidiaries dissolve, liquidate or merge with any other person or entity (unless, in the case of such a merger, the Company or, in the case of merger not involving the Company, such other Credit
Party or, if no Credit Party is involved, such Subsidiary, as applicable, is the surviving entity); 
 (c) become subject to
(including, without limitation, by way of amendment to or modification of) any agreement or instrument which by its terms would (under any circumstances) restrict the Company’s or any of its Subsidiaries, right to perform the provisions of this
Agreement, any Related Agreement or any of the agreements contemplated hereby or thereby; 
 (d) materially alter or change
the nature of the business of the Company and its Subsidiaries taken as a whole away from the biotechnology industry as reasonably determined by the Purchaser; or 
 (e) (i) create, incur, assume or suffer to exist any indebtedness (exclusive of trade debt and debt incurred to finance the purchase
of equipment (not in excess of five percent (5%) of the fair market value of the Company’s and its Subsidiaries’ assets)) whether secured or unsecured other than (w) the Company’s obligations owed to the Purchaser,
(x) indebtedness set forth on Schedule 6.12(e) attached hereto and made a part hereof and any refinancings or replacements thereof on terms no less favorable to the Purchaser than the indebtedness being refinanced or replaced, (y) any
indebtedness incurred in connection with the purchase of assets (other than equipment) in the ordinary course of business, or any refinancings or replacements thereof on terms no less favorable to the Purchaser than the indebtedness being refinanced
or replaced, so long as any lien relating thereto shall only encumber the fixed assets so purchased and no other assets of the Company or any of its Subsidiaries and (z) indebtedness evidenced by the New Market Transaction Documents; provided
that such New Market Transaction Documents are reasonably satisfactory to the Purchaser; provided further that such indebtedness evidenced in such New Market Transaction Documents shall be unsecured and expressly 
  

 22 








 subordinated in right of payment to the indebtedness owed by the Company and its Subsidiaries to the
Purchaser; (ii) cancel any indebtedness owing to it in excess of $50,000 in the aggregate during any 12 month period; (iii) assume, guarantee, endorse or otherwise become directly or contingently liable in connection with any obligations
of any other person or entity, except the endorsement of negotiable instruments by the Company or any Credit Party for deposit or collection or similar transactions in the ordinary course of business or guarantees of indebtedness otherwise permitted
to be outstanding pursuant to this clause (e); 
 (f) purchase or hold beneficially any Stock or other securities or evidences
of indebtedness of, make or permit to exist any loans or advances to, or make any investment or acquire any interest whatsoever in, any other Person, including any partnership or joint venture, except (x) travel advances, (y) loans to its
and its Subsidiaries’ officers and employees not exceeding at any one time an aggregate of $10,000, and (z) loans or advances to any Credit Parties (as used herein, “Stock” means all certificated and uncertificated shares,
options, warrants, membership interests, general or limited partnership interests, participation or other equivalents (regardless of how designated) of or in a corporation, partnership, limited liability company or equivalent entity whether voting
or nonvoting, including common stock, preferred stock, or any other “equity security” (as such term is defined in Rule 3a11-1 of the General Rules and Regulations promulgated by the SEC under the Securities Exchange Act of 1934));

 (g) except for the commercialization agreement between the Company and the Parent as in effect on the date hereof enter
into any transaction with any employee, director or Affiliate, except in the ordinary course on arms-length terms (as used herein (x) “Affiliate” means, with respect to any Person, (a) any other Person (other than a
Subsidiary) which, directly or indirectly, is in control of, is controlled by, or is under common control with such Person or (b) any other Person who is a director or officer (i) of such Person, (ii) of any Subsidiary of such Person
or (iii) of any Person described in clause (a) above. For the purposes of this definition, control of a Person shall mean the power (direct or indirect) to direct or cause the direction of the management and policies of such Person whether
by contract or otherwise and (y) “Person” means any individual, sole proprietorship, partnership, limited liability partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability
company, institution, public benefit corporation, entity or government (whether federal, state, county, city, municipal or otherwise, including any instrumentality, division, agency, body or department thereof), and shall include such Person’s
successors and assigns); and 
 (h) sell, lease, transfer or otherwise dispose of any of its properties or assets, or any of
the properties or assets of its Subsidiaries, except for (1) sales, leases, transfer or dispositions by any Credit Party to any other Credit Party, (2) the sale of Inventory (as defined in the Master Security Agreement) in the ordinary
course of business and (3) the disposition or transfer in the ordinary course of business during any fiscal year of obsolete and worn-out Equipment (as defined in the Master Security Agreement) and only to the extent that (x) the proceeds
of any such disposition are used to acquire replacement Equipment which is subject to the Purchaser’s first priority security interest or are used to repay the Purchaser or to pay general corporate expenses, or (y) following 
  

 23 








 the occurrence of an Event of Default (as defined in the Note) which continues to exist, the proceeds of
which are remitted to the Purchaser to be held as cash collateral for the Obligations (as defined in the Master Security Agreement). 
 (II)
The Company, without the prior written consent of the Purchaser, shall not, and shall not permit any of its Subsidiaries to, create or acquire any Subsidiary after the date hereof unless (i) such Subsidiary is a wholly-owned Subsidiary of the
Company or an international Subsidiary (which may have shareholders) and (ii) except for international Subsidiaries referenced in (i) above, each such Subsidiary becomes a party to the Master Security Agreement, the Stock Pledge Agreement
and the Subsidiary Guaranty (either by executing a counterpart thereof or an assumption or joinder agreement in respect thereof) and, to the extent required by the Purchaser, satisfies each condition of this Agreement and the Related Agreements as
if such Subsidiary were a Subsidiary on the Closing Date. It is agreed and understood that to the extent that any international Subsidiary that is created or acquired after the date hereof is a non-Credit Party (each, a “New Non-Credit Party
Subsidiary”), the capitalization of such New Non-Credit Party Subsidiary shall come from sources other than the Company or any of its other Subsidiaries. Furthermore, the Company and its Subsidiaries (other than the New Non-Credit Party
Subsidiaries) shall otherwise be prohibited from investing in, lending to, contributing and/or transferring any assets to and/or providing any form of financial assistance to, whether directly or indirectly, such New Non-Credit Party Subsidiary;
provided that this prohibition does not limit the Company or a New Non-Credit Party Subsidiary from entering into a license agreement (to be negotiated on an arm’s length basis) to sell its instrumentation internationally on a cost plus basis.
Notwithstanding the foregoing, it is agreed and understood that immediately upon the capitalization and constitution of the management group of BioLender, LLC, a Delaware limited liability company (“BioLender”), but in no event later than
April 30, 2006, BioLender shall become a party to the Master Security Agreement, the Stock Pledge Agreement and the Subsidiary Guaranty (either by executing a counterpart thereof or an assumption or joinder agreement in respect thereof) and
shall satisfy each condition of this Agreement and the Related Agreements as if BioLender were a Subsidiary on the Closing Date. 
 (III) The
Company shall not, and shall not permit any of its Subsidiaries to, without the prior written consent of the Purchaser, amend, modify or in any way alter the terms of any of the Subordinated Debt Documentation. 
 (IV) The Company shall not, and shall not permit any of its Subsidiaries to, without the prior written consent of the Purchaser, grant or permit any of
its Subsidiaries to grant to any Person any Collateral (as defined in the Security Documents, as applicable) of such company or any collateral of any of its Subsidiaries as security for any obligation arising under the Subordinated Debt
Documentation. 
 (V) Except as set forth on Schedule 6.12(V), neither the Company nor any of its Subsidiaries shall, without the prior
written consent of the Purchaser, make any payments in respect of the indebtedness evidenced by the Subordinated Debt Documentation, other than as expressly permitted by the terms thereof. 
  

 24 








 6.13 Reissuance of Securities. The Company agrees to reissue certificates representing the
Securities without the legends set forth in Section 5.8 above at such time as: 
 (a) the holder thereof is permitted to
dispose of such Securities pursuant to Rule 144(k) under the Securities Act; or 
 (b) upon resale subject to an effective
registration statement after such Securities are registered under the Securities Act. 
 The Company agrees to cooperate with the Purchaser in connection
with all resales pursuant to Rule 144(d) and Rule 144(k) and provide legal opinions necessary to allow such resales provided the Company and its counsel receive reasonably requested representations from the Purchaser and broker, if any. 

6.14 Opinion. On the Closing Date, the Company will deliver to the Purchaser an opinion acceptable to the Purchaser from the Company’s
in-house legal counsel. The Company will provide, at the Company’s expense, such other legal opinions in the future as are deemed reasonably necessary by the Purchaser (and acceptable to the Purchaser) in connection with the exercise of the
Warrant. 
 6.15 Margin Stock. The Company will not permit any of the proceeds of the Note or the Warrant to be used directly or
indirectly to “purchase” or “carry” “margin stock” or to repay indebtedness incurred to “purchase” or “carry” “margin stock” within the respective meanings of each of the quoted terms under
Regulation U of the Board of Governors of the Federal Reserve System as now and from time to time hereafter in effect. 
 6.16 Restricted
Cash Disclosure. The Company agrees that, in connection with its filing of its 8-K Report with the SEC concerning the transactions contemplated by this Agreement and the Related Agreements (such report, the “Laurus Transaction 8-K”) in
a timely manner after the date hereof, it will disclose in such Laurus Transaction 8-K the amount of the proceeds of the Note issued to the Purchaser that has been placed in a restricted cash account and is subject to the terms and conditions of
this Agreement and the Related Agreements. Furthermore, the Company agrees to disclose in all public filings required by the Commission (where appropriate) following the filing of the Laurus Transaction 8-K, the existence of the restricted cash
referred to in the immediately preceding sentence, together with the amount thereof. 
 6.17 Financing Right of First Refusal.

 (a) So long as the Company and/or any of its Subsidiaries has outstanding Obligations (as defined in the Master Security
Agreement) to the Purchaser, the Company hereby grants to the Purchaser a right of first refusal to provide any Additional Financing (as defined below) to be issued by the Company and/or any of its Subsidiaries, subject to the following terms and
conditions. From and after the date hereof, prior to the incurrence of any additional indebtedness (both convertible and non-convertible) not otherwise permitted herein of the Company or any of its Subsidiaries (an “Additional Financing”),
the Company and/or any Subsidiary of the Company, as the case may be, shall notify the Purchaser of its intention to enter into such Additional Financing. In 
  

 25 








 connection therewith, the Company and/or the applicable Subsidiary thereof shall submit a fully executed
term sheet (a “Proposed Term Sheet”) to the Purchaser setting forth the terms, conditions and pricing of any such Additional Financing (such financing to be negotiated on “arm’s length” terms and the terms thereof to be
negotiated in good faith) proposed to be entered into by the Company and/or such Subsidiary. For the avoidance of doubt, this right of first refusal does not include any right with respect to the New Market Transaction Documents. The Purchaser shall
have the right, but not the obligation, to deliver its own proposed term sheet (the “Purchaser Term Sheet”) setting forth the terms and conditions upon which the Purchaser would be willing to provide such Additional Financing to the
Company and/or such Subsidiary. The Purchaser Term Sheet shall contain terms no less favorable to the Company and/or such Subsidiary than those outlined in Proposed Term Sheet. The Purchaser shall deliver such Purchaser Term Sheet within ten
business days of receipt of each such Proposed Term Sheet. If the provisions of the Purchaser Term Sheet are at least as favorable to the Company and/or such Subsidiary, as the case may be, as the provisions of the Proposed Term Sheet, the Company
and/or such Subsidiary shall enter into and consummate the Additional Financing transaction outlined in the Purchaser Term Sheet. 
 (b) The Company will not, and will not permit its Subsidiaries to except for those that are New Non-Credit Party Subsidiaries, agree, directly or indirectly, to any restriction with any person or entity which limits the ability of the
Purchaser to consummate an Additional Financing with the Company or any of its Subsidiaries. 
 6.18 Authorization and Reservation of
Shares. The Company shall at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the exercise of the Warrants. 
 7. Covenants of the Purchaser. The Purchaser covenants and agrees with the Company as follows: 
 7.1
Confidentiality. The Purchaser will not disclose, and will not include in any public announcement, the name of the Company, unless expressly agreed to by the Company or unless and until such disclosure is required by law or applicable
regulation, and then only to the extent of such requirement. 
 7.2 Non-Public Information. The Purchaser will not effect any sales in
the shares of the Company’s Common Stock while in possession of material, non-public information regarding the Company if such sales would violate applicable securities law. 
 7.3 Limitation on Acquisition of Common Stock of the Company. Notwithstanding anything to the contrary contained in this Agreement, any Related
Agreement or any document, instrument or agreement entered into in connection with any other transactions between the Purchaser and the Company, the Purchaser may not acquire stock in the Company (including, without limitation, pursuant to a
contract to purchase, by exercising an option or warrant, by converting any other security or instrument, by acquiring or exercising any other right to acquire, shares of stock or other security convertible into shares of stock in the Company, or
otherwise, and such contracts, options, warrants, conversion or other rights shall not be 
  

 26 








 enforceable or exercisable) to the extent such stock acquisition would cause any interest (including any original issue
discount) payable by the Company to the Purchaser not to qualify as “portfolio interest” within the meaning of Section 881(c)(2) of the Code, by reason of Section 881(c)(3) of the Code, taking into account the constructive
ownership rules under Section 871(h)(3)(C) of the Code (the “Stock Acquisition Limitation”). The Stock Acquisition Limitation shall automatically become null and void without any notice to the Company upon the earlier to occur of
either (a) the Company’s delivery to the Purchaser of a Notice of Prepayment (as defined in the Note) or (b) the existence of an Event of Default (as defined in the Note) at a time when the average closing price of the Company’s
common stock as reported by Bloomberg, L.P. on the Principal Market for the immediately preceding five trading days is greater than or equal to 150% of the Exercise Price (as defined in the Warrant). 
 8. Covenants of the Company and the Purchaser Regarding Indemnification. 
 8.1 Company Indemnification. The Company agrees to indemnify, hold harmless, reimburse and defend the Purchaser, each of the Purchaser’s
officers, directors, agents, affiliates, control persons, and principal shareholders, against all claims, costs, expenses, liabilities, obligations, losses or damages (including reasonable legal fees) of any nature, incurred by or imposed upon the
Purchaser which result, arise out of or are based upon: (i) any misrepresentation by the Company or any of its Subsidiaries or breach of any warranty by the Company or any of its Subsidiaries in this Agreement, any other Related Agreement or in
any exhibits or schedules attached hereto or thereto; or (ii) any breach or default in performance by Company or any of its Subsidiaries of any covenant or undertaking to be performed by Company or any of its Subsidiaries hereunder, under any
other Related Agreement or any other agreement entered into by the Company and/or any of its Subsidiaries and the Purchaser relating hereto or thereto. 
 8.2 Purchaser’s Indemnification. The Purchaser agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, affiliates, control persons
and principal shareholders, at all times against any claims, costs, expenses, liabilities, obligations, losses or damages (including reasonable legal fees) of any nature, incurred by or imposed upon the Company which result, arise out of or are
based upon: (i) any misrepresentation by the Purchaser or breach of any warranty by the Purchaser in this Agreement or in any exhibits or schedules attached hereto or any Related Agreement; or (ii) any breach or default in performance by
the Purchaser of any covenant or undertaking to be performed by the Purchaser hereunder, or any other agreement entered into by the Company and the Purchaser relating hereto. 
 9. Exercise of Warrant. 
 9.1
Mechanics of Exercise. 
 (a) Provided the Purchaser has notified the Company of the Purchaser’s intention to sell
the Warrant Shares and the Warrant Shares are included in an effective registration statement or are otherwise exempt from registration when sold: (i) upon the exercise of the Warrant or part thereof, the Company shall, at its own cost and
expense, take all necessary action (including the issuance of an opinion of counsel reasonably 
  

 27 








 acceptable to the Purchaser following a request by the Purchaser) to assure that the Company’s
transfer agent shall issue shares of the Company’s Common Stock in the name of the Purchaser (or its nominee) or such other persons as designated by the Purchaser in accordance with Section 9.1(b) hereof and in such denominations to be
specified representing the number of Warrant Shares issuable upon such exercise; and (ii) the Company warrants that no instructions other than these instructions have been or will be given to the transfer agent of the Company’s Common
Stock and that after the Effectiveness Date (as defined in the Registration Rights Agreement) the Warrant Shares issued will be freely transferable subject to the prospectus delivery requirements of the Securities Act and the provisions of this
Agreement, and will not contain a legend restricting the resale or transferability of the Warrant Shares. 
 (b) The Purchaser
will give notice of its decision to exercise its right to exercise the Warrant or part thereof by telecopying or otherwise delivering an executed and completed notice of the number of shares to be exercised to the Company (the “Form of
Subscription”). The Purchaser will not be required to surrender the Warrant until the Purchaser receives a credit to the account of the Purchaser’s prime broker through the DWAC system (as defined below), representing all the Warrant
Shares issuable under the Warrant. Each date on which a Form of Subscription is telecopied or delivered to the Company in accordance with the provisions hereof shall be deemed an “Exercise Date.” Pursuant to the terms of the Form of
Subscription, the Company will issue instructions to the transfer agent accompanied by an opinion of counsel within two (2) business days of the date of the delivery to the Company of the Form of Subscription and shall cause the transfer agent
to transmit the certificates representing the Warrant Shares set forth in the applicable Form of Subscription to the Holder by crediting the account of the Purchaser’s prime broker with the Depository Trust Company (“DTC”) through its
Deposit Withdrawal Agent Commission (“DWAC”) system within three (3) business days after receipt by the Company of the Form of Subscription (the “Delivery Date”). 
 (c) The Company understands that a delay in the delivery of the Warrant Shares in the form required pursuant to Section 9 hereof
beyond the Delivery Date could result in economic loss to the Purchaser. In the event that the Company fails to direct its transfer agent to deliver the Warrant Shares to the Purchaser via the DWAC system within the time frame set forth in
Section 9.1(b) above and the Warrant Shares are not delivered to the Purchaser by the Delivery Date, as compensation to the Purchaser for such loss, the Company agrees to pay late payments to the Purchaser for late issuance of the Warrant
Shares in the form required pursuant to Section 9 hereof upon exercise of the Warrant in the amount equal to the greater of: (i) $500 per business day after the Delivery Date; or (ii) the Purchaser’s actual damages from such
delayed delivery. The Company shall pay any payments incurred under this Section in immediately available funds upon demand and, in the case of actual damages, accompanied by reasonable documentation of the amount of such damages. Such documentation
shall show the number of shares of Common Stock the Purchaser is forced to purchase (in an open market transaction) which the Purchaser anticipated receiving upon such exercise, and shall be calculated as the amount by which (A) the
Purchaser’s total purchase price (including customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (B) the aggregate exercise price of the Warrant, for which such Form of Subscription was not timely
honored. 
  

 28 








 10. Registration Rights. 
 10.1 Registration Rights Granted. The Company hereby grants registration rights to the Purchaser pursuant to the Registration Rights Agreement.

 10.2 Offering Restrictions. Except as previously disclosed in the SEC Reports or in the Exchange Act Filings, or stock or stock
options granted to employees or directors of the Company (these exceptions hereinafter referred to as the “Excepted Issuances”), neither the Company nor any of its Subsidiaries will, prior to the full exercise by Purchaser of the Warrants,
(x) enter into any equity line of credit agreement or similar agreement or (y) issue, or enter into any agreement to issue, any securities with a variable/floating conversion and/or pricing feature which are or could be (by conversion or
registration) free-trading securities (i.e. common stock subject to a registration statement). 
 11. Miscellaneous. 
 11.1 Governing Law, Jurisdiction and Waiver of Jury Trial. 
 (a) THIS AGREEMENT AND THE OTHER RELATED AGREEMENTS SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. 
 (b) THE PARTIES HEREBY CONSENT AND AGREE THAT THE STATE OR FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE COMPANY, ON THE ONE
HAND, AND THE PURCHASER, ON THE OTHER HAND, PERTAINING TO THIS AGREEMENT OR ANY OF THE RELATED AGREEMENTS OR TO ANY MATTER ARISING OUT OF OR RELATED TO THIS AGREEMENT OR ANY OF THE OTHER RELATED AGREEMENTS; PROVIDED, THAT THE PURCHASER AND
THE COMPANY ACKNOWLEDGE THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK; AND FURTHER PROVIDED, THAT, NOTHING IN THIS AGREEMENT SHALL BE DEEMED OR OPERATE
TO PRECLUDE THE PURCHASER FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO COLLECT THE OBLIGATIONS, TO REALIZE ON THE COLLATERAL (AS DEFINED IN THE MASTER SECURITY AGREEMENT) OR ANY OTHER SECURITY FOR THE OBLIGATIONS (AS
DEFINED IN THE MASTER SECURITY AGREEMENT), OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE PURCHASER. THE COMPANY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED 
  

 29 








 IN ANY SUCH COURT, AND THE COMPANY HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON LACK OF
PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS. THE COMPANY HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINT AND
OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE COMPANY AT THE ADDRESS SET FORTH IN SECTION 11.9 AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF THE COMPANY’S ACTUAL RECEIPT THEREOF OR THREE
(3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID. 
 (c) THE PARTIES DESIRE THAT THEIR DISPUTES BE
RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, THE PARTIES HERETO WAIVE ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT
TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN THE PURCHASER AND/OR THE COMPANY ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS AGREEMENT,
ANY OTHER RELATED AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO. 
 11.2 Severability. Wherever possible each provision of
this Agreement and the Related Agreements shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or any Related Agreement shall be prohibited by or invalid or illegal under
applicable law such provision shall be ineffective to the extent of such prohibition or invalidity or illegality, without invalidating the remainder of such provision or the remaining provisions thereof which shall not in any way be affected or
impaired thereby. 
 11.3 Survival. The representations, warranties, covenants and agreements made herein shall survive any
investigation made by the Purchaser and the closing of the transactions contemplated hereby to the extent provided therein. All statements as to factual matters contained in any certificate or other instrument delivered by or on behalf of the
Company pursuant hereto in connection with the transactions contemplated hereby shall be deemed to be representations and warranties by the Company hereunder solely as of the date of such certificate or instrument. All indemnities set forth herein
shall survive the execution, delivery and termination of this Agreement and the Note and the making and repayment of the obligations arising hereunder, under the Note and under the other Related Agreements. 
 11.4 Successors. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the
successors, heirs, executors and administrators of the parties hereto and shall inure to the benefit of and be enforceable by each person or entity which shall be a holder of the Securities from time to time, other than the holders of Common Stock
which has been sold by the Purchaser pursuant to Rule 144 or an 
  

 30 








 effective registration statement. The Purchaser shall not be permitted to assign its rights hereunder or under any
Related Agreement to a competitor of the Company unless an Event of Default (as defined in the Note) has occurred and is continuing. 
 11.5
Entire Agreement; Maximum Interest. This Agreement, the Related Agreements, the exhibits and schedules hereto and thereto and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein and therein. Nothing contained in this
Agreement, any Related Agreement or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum rate permitted by
applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum rate permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the
Company to the Purchaser and thus refunded to the Company. 
 11.6 Amendment and Waiver. 
 (a) This Agreement may be amended or modified only upon the written consent of the Company and the Purchaser. 
 (b) The obligations of the Company and the rights of the Purchaser under this Agreement may be waived only with the written consent of the
Purchaser. 
 (c) The obligations of the Purchaser and the rights of the Company under this Agreement may be waived only with
the written consent of the Company. 
 11.7 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power
or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement or the Related Agreements, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach,
default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. All remedies, either under this Agreement or the Related Agreements, by law or otherwise afforded to any party,
shall be cumulative and not alternative. 
 11.8 Notices. All notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: 
 (a) upon personal delivery to the party to be notified; 
 (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day;

 (c) three (3) business days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or 
  

 31 








 (d) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. 
 All communications shall be sent as follows:

  

			
	If to the Company, to:	  	 Biovest International, Inc.
 377 Plantation
Street
 Worcester, MA 01605
 Attention:      Chief Financial Officer
 Facsimile:      813-258-6912

		
		  	with a copy to:
		
		  	 Nixon Peabody LLP
 401 Ninth Street, N.W., Suite
900
 Washington, DC 20004
 Attention:      Herbert F. Stevens, Esq.
 Facsimile:      202-585-8080

		
	If to the Purchaser, to:	  	 Laurus Master Fund, Ltd.
 c/o M&C Corporate Services
Limited
 P.O. Box 309 GT
 Ugland House
 George Town
 South Church Street
 Grand Cayman, Cayman Islands
 Facsimile:      345-949-8080

		
		  	with a copy to:
		
		  	 John E. Tucker, Esq.
 825 Third Avenue 14th
Floor
 New York, NY 10022
 Facsimile:      212-541-4434


 or at such other address as the Company or the Purchaser may designate by written notice to the other parties
hereto given in accordance herewith. 
 11.9 Attorneys’ Fees. In the event that any suit or action is instituted to enforce any
provision in this Agreement or any Related Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this
Agreement and/or such Related Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
  

 32 








 11.10 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for
convenience of reference only and are not to be considered in construing this Agreement. 
 11.11 Facsimile Signatures; Counterparts.
This Agreement may be executed by facsimile signatures and in any number of counterparts, each of which shall be an original, but all of which together shall constitute one agreement. 
 11.12 Broker’s Fees. Except as set forth on Schedule 11.12 hereof, each party hereto represents and warrants that no agent, broker,
investment banker, person or firm acting on behalf of or under the authority of such party hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection with the transactions
contemplated herein. Each party hereto further agrees to indemnify each other party for any claims, losses or expenses incurred by such other party as a result of the representation in this Section 11.12 being untrue. 
 11.13 Construction. Each party acknowledges that its legal counsel participated in the preparation of this Agreement and the Related Agreements
and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Agreement or any Related Agreement to favor any party against the other.

 [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK 
  

 33 








 IN WITNESS WHEREOF, the parties hereto have executed the NOTE AND WARRANT PURCHASE AGREEMENT as of the date set forth in
the first paragraph hereof. 
  

									
	COMPANY:	 		 	PURCHASER:
			
	BIOVEST INTERNATIONAL, INC.	 		 	LAURUS MASTER FUND, LTD.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  


  

 34 








 EXHIBIT A 
 FORM OF SECURED PROMISSORY NOTE 
  

 A-1 








 EXHIBIT B 
 FORM OF WARRANT 
  

 B-1 








 EXHIBIT C 
 FORM OF ESCROW AGREEMENT 
  

 D-1